Actelion Pharmaceuticals Ltd is a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, focusing on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs.

Actelion presents its strategy for value creation

Jean-Paul Clozel, CEO “I am committed to value creation
for our shareholders. After the promising macitentan
results, Actelion will more than ever continue its effort
in the PAH market."

Journalist support
Investor webcast

Jean-Paul Clozel, CEO “I am committed to value creation
for our shareholders. After the promising macitentan
results, Actelion will more than ever continue its effort
in the PAH market."

Journalist support
Investor webcast

Global Actelion

Worldmap imageWorldmap image

Actelion has subsidaries in over 30 countries, covering all major pharmaceutical markets worldwide

Explore our operations
 

Latest news

08 May 2012Actelion presents its strategy for value creation
04 May 2012Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland
02 May 2012Actelion to host Company Update Conference Call / Audiocast
30 Apr 2012Actelion's macitentan meets primary endpoint in pivotal Phase III SERAPHIN outcome study in patients with pulmonary arterial hypertension
View all news

Share price

ATLN SIX Swiss Exchange

At 17:31:17 CEST 16/05/2012
CHF 38,23Up Down image
+0,18 (+0,47%)
Further stock information